(Total Views: 619)
Posted On: 03/26/2021 9:07:22 PM
Post# of 153917
I'm glad leronlimab doesn't have the problem bamlanivimab does which relates to the "sustained increase" in coronavirus variants in the United States.
3. 6:06 We believe leronlimab is not dependent on whether the virus is the wild-type virus or a variant. Our target is not the virus... Our goal is to restore immune function in the sickest Covid19 patients.
34. 35:15 We do not need separate trials for the variants. Leronlimab will not be affected by the variants because of the target. That is our advantage.
Read More: https://investorshangout.com/post/view?id=6093110
3. 6:06 We believe leronlimab is not dependent on whether the virus is the wild-type virus or a variant. Our target is not the virus... Our goal is to restore immune function in the sickest Covid19 patients.
34. 35:15 We do not need separate trials for the variants. Leronlimab will not be affected by the variants because of the target. That is our advantage.
Read More: https://investorshangout.com/post/view?id=6093110
(4)
(0)
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
